liarozole has been researched along with Prostatic Neoplasms in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 23 (82.14) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodie, AM; Clement, OO; Gediya, LK; Goloubeva, OG; Handratta, VD; Huynh, CK; Nanne, IP; Njar, VC; Patel, JB; Soprano, DR | 1 |
| Alonso, A; Burzykowski, T; Buyse, M; Molenberghs, G | 1 |
| Leroux, F | 1 |
| Boccardo, F; Bono, A; Cannata, D; Cortesi, E; Guarneri, D; Oneto, F | 1 |
| Borgers, M; Coene, MC; Daneels, G; De Coster, R; Moeremans, M; Ramaekers, FC; Schalken, JA; Smets, G; Van Ginckel, R; Van Wauwe, J | 1 |
| de Coster, R; Debruyne, FM; Dijkman, GA; Schalken, JA; Van Ginckel, R; Van Moorselaar, RJ; Van Stratum, P; Wouters, L | 1 |
| Fudge, K; Stearns, ME; Wang, M | 1 |
| Denis, L; Mahler, C; Verhelst, J | 2 |
| Hall, SW; Kreis, W; Kremer, AB; Kurman, MR; Ouyang, SP; Seidmon, EJ; Trump, DL; Wu, J | 1 |
| Bruynseels, J; De Coster, R; Wouters, W | 1 |
| Coene, MC; Cools, W; Janssens, B; Krekels, MD; Van Ginckel, R; Van Hove, C; Wouters, W; Zimmerman, J | 1 |
| Hall, AK | 1 |
| Bryson, HM; Wagstaff, AJ | 1 |
| Bruynseels, J; de Porre, P; Debruyne, FM; Denis, L; Dijkman, GA; Fernandez del Moral, P | 1 |
| Akaza, H | 1 |
| Denis, L | 1 |
| Boccardo, F; Brune, D; Bruynseels, J; De Porre, P; Debruyne, FJ; Denis, L; Fradet, Y; Janssens, M; Johansson, JE; Marberger, JM; Murray, R; Rassweiler, J; Tyrrell, C; Vangeneugden, T | 1 |
| Roylance, R; Waxman, J | 1 |
| Bruynseels, J; De Porre, P; Debruyne, F; Denis, L | 1 |
| Feldman, D; Holloway, L; Ly, LH; Zhao, XY | 1 |
| Hosaka, M; Takeda, M | 1 |
| Denis, L; Mahler, C | 1 |
| Kriegmair, M; Schmeller, NT | 1 |
| De Coster, R; Distelmans, W; Goeminne, N; Jagers, E; Van Cauteren, H; van der Veer, R; Van Ginckel, R; Vanherck, W; Wouters, L; Wouters, W | 1 |
| De Coster, R; Denis, L; Mahler, C | 1 |
7 review(s) available for liarozole and Prostatic Neoplasms
| Article | Year |
|---|---|
Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Male; Molecular Structure; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2005 |
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Glucocorticoids; Humans; Imidazoles; Ketoconazole; Male; Middle Aged; Mineralocorticoids; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Remission Induction; Testosterone | 1993 |
P450-dependent enzymes as targets for prostate cancer therapy.
Topics: Adenocarcinoma; Aldehyde-Lyases; Androgen Antagonists; Androgens; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Cattle; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Imidazoles; Ketoconazole; Male; Mice; Neoplasm Proteins; Prostatic Neoplasms; Rats; Rats, Wistar; Salvage Therapy; Steroid 17-alpha-Hydroxylase; Tretinoin; Tumor Cells, Cultured | 1996 |
[Development of new drugs for urological cancers].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Cytosine; Humans; Imidazoles; Kidney Neoplasms; Male; Prostatic Neoplasms | 1997 |
[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Topics: 17-Hydroxysteroid Dehydrogenases; Androgen Antagonists; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carbazoles; Enzyme Inhibitors; Humans; Imidazoles; Ketoconazole; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2000 |
Management of relapsing disease in prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens; Humans; Imidazoles; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Palliative Care; Prostatic Neoplasms; Recurrence | 1992 |
[New substances in therapy of advanced prostate cancer].
Topics: Androgen Antagonists; Humans; Imidazoles; Immunologic Factors; Male; Neoplasm Staging; Palliative Care; Prostatic Neoplasms; Suramin | 1991 |
7 trial(s) available for liarozole and Prostatic Neoplasms
| Article | Year |
|---|---|
R75251 in prostate cancer patients in progression after first-line hormonal treatment.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Drug Administration Schedule; Humans; Hydrocortisone; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Treatment Outcome | 1994 |
Phase I liarozole studies in advanced prostate cancer show encouraging results.
Topics: Antineoplastic Agents; Humans; Imidazoles; Male; Prostatic Neoplasms | 1994 |
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Glucocorticoids; Humans; Imidazoles; Ketoconazole; Male; Middle Aged; Mineralocorticoids; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Remission Induction; Testosterone | 1993 |
Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Imidazoles; Male; Maximum Allowable Concentration; Middle Aged; Prostatic Neoplasms; Treatment Outcome | 1995 |
Liarozole (R75251) in hormone-resistant prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Drug Resistance; Hormones; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 1997 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Castration; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Epirubicin; Estramustine; Flutamide; Humans; Imidazoles; Male; Medroxyprogesterone Acetate; Methotrexate; Mitomycin; Neoplasms, Hormone-Dependent; Procarbazine; Prostatic Neoplasms; Vindesine | 1998 |
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1998 |
15 other study(ies) available for liarozole and Prostatic Neoplasms
| Article | Year |
|---|---|
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cricetinae; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Microsomes, Liver; Neoplasm Transplantation; Prostatic Neoplasms; Retinoic Acid 4-Hydroxylase; Stereoisomerism; Transplantation, Heterologous; Tretinoin | 2004 |
A perspective on surrogate endpoints in controlled clinical trials.
Topics: Antineoplastic Agents, Hormonal; Biomarkers; Controlled Clinical Trials as Topic; Humans; Imidazoles; Male; Models, Statistical; Predictive Value of Tests; Prostatic Neoplasms; Treatment Outcome | 2004 |
Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Imidazoles; Immunoblotting; Immunohistochemistry; Keratins; Male; Neoplasm Transplantation; Organ Size; Prostate; Prostatic Neoplasms; Random Allocation; Rats; Rats, Inbred F344; Tretinoin; Tumor Cells, Cultured; Vimentin | 1995 |
Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
Topics: Adenocarcinoma; Androgens; Animals; Antineoplastic Agents; Imidazoles; Male; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1994 |
Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Adhesion; Cell Division; Cell Survival; Chemotactic Factors; Collagenases; Disease Models, Animal; Humans; Imidazoles; Isotretinoin; Male; Matrix Metalloproteinase 9; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Prostatic Neoplasms; Tumor Cells, Cultured | 1993 |
Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumors.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Female; Imidazoles; Kinetics; Liver; Male; NADP; Oxidation-Reduction; Prostatic Neoplasms; Rats; Rats, Wistar; Tretinoin | 1996 |
New molecules and treatment modulation in advanced prostatic cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Male; Nitriles; Prostatic Neoplasms; Retinoids; Somatostatin; Suramin; Tosyl Compounds | 1996 |
Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; beta Carotene; Blotting, Northern; Cell Division; DNA Fragmentation; Drug Synergism; Genes, bcl-2; Humans; Imidazoles; Male; Prostatic Neoplasms; Retinoids; RNA, Messenger; Thymosin; Tretinoin; Tumor Cells, Cultured | 1996 |
Liarozole.
Topics: Animals; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Humans; Imidazoles; Male; Prostatic Neoplasms | 1996 |
New drugs for prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Prostatic Neoplasms; Retinoids | 1998 |
Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Hormones; Humans; Imidazoles; Male; Middle Aged; Pain; Pain Measurement; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1998 |
Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Calcitriol; Cell Division; Drug Synergism; Enzyme Inhibitors; Half-Life; Humans; Imidazoles; Male; Prostatic Neoplasms; Receptors, Calcitriol; Tumor Cells, Cultured | 1999 |
Liarozole. Liarozole fumarate, Liazal, R 75251, R 85246.
Topics: Aromatase Inhibitors; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Humans; Imidazoles; Male; Prostatic Neoplasms | 1999 |
Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Imidazoles; Male; Neoplasm Transplantation; Orchiectomy; Prostatic Neoplasms; Rats; Rats, Inbred F344; Testosterone | 1990 |
The effects of a new imidazole derivative in advanced prostatic cancer. A preliminary report.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Humans; Imidazoles; Ketoconazole; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms | 1989 |